目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS SEGMENTATION
1.3.2 YEARS CONSIDERED
1.3.3 INCLUSIONS AND EXCLUSIONS
1.3.4 CURRENCY CONSIDERED
1.4 MARKET STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.2 RESEARCH METHODOLOGY DESIGN
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 MARKET ASSUMPTIONS
2.6.1 INFUSION PUMPS MARKET: ASSUMPTION ANALYSIS
2.6.2 GROWTH RATE ASSUMPTIONS
2.7 RISK ASSESSMENT
2.8 LIMITATIONS
2.8.1 METHODOLOGY-RELATED LIMITATIONS
2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 INFUSION PUMPS MARKET OVERVIEW
4.2 ASIA PACIFIC: INFUSION PUMPS MARKET, BY APPLICATION & COUNTRY (2024)
4.3 INFUSION PUMPS MARKET: REGIONAL MIX
4.4 INFUSION PUMPS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.5 INFUSION PUMPS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Technological innovation for development of automated pumps
5.2.1.2 Stringent regulatory guidelines for safety & cybersecurity requirements
5.2.1.3 Increasing demand for ambulatory infusion pumps in home care settings
5.2.1.4 Expanding geriatric population and subsequent rise in chronic diseases
5.2.1.5 Rising number of surgical procedures
5.2.2 RESTRAINTS
5.2.2.1 Product recalls
5.2.2.2 Complex regulatory process for product commercialization
5.2.2.3 Increasing adoption of refurbished & rental infusion pumps
5.2.3 OPPORTUNITIES
5.2.3.1 Growth potential of emerging economies
5.2.3.2 Increasing adoption of specialty infusion systems
5.2.4 CHALLENGES
5.2.4.1 Rising incidence of medication errors and lack of wireless connectivity in hospitals
5.3 INDUSTRY TRENDS
5.3.1 GROWING FOCUS ON SMART PUMP-EMR INTEROPERABILITY
5.3.2 DEVELOPMENT OF HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS
5.3.3 INCREASING DEMAND FOR SPECIALTY PUMPS AND ADVANCED FEATURES
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Flow generation
5.4.1.2 Smart infusion systems
5.4.1.3 Closed-loop infusion control systems
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Dose-error reduction systems
5.4.2.2 Wireless connectivity
5.4.2.3 AI-powered decision support systems
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Embedded software
5.4.3.2 Sensing technology
5.4.3.3 Telemedicine platforms
5.5 PORTER'S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 BARGAINING POWER OF BUYERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY LANDSCAPE
5.6.1 REGULATORY ANALYSIS
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 PATENT ANALYSIS
5.7.1 PATENT PUBLICATION TRENDS FOR INFUSION PUMPS
5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
5.8 TRADE ANALYSIS
5.8.1 TRADE DATA FOR HS CODE 901890
5.8.1.1 Import data for HS Code 901890
5.8.1.2 Export data for HS Code 901890
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE, BY KEY PLAYER
5.9.1.1 Average selling price trend of key players, by device
5.9.2 AVERAGE SELLING PRICE, BY REGION
5.9.2.1 Average selling price of volumetric infusion pumps, insulin pumps, and syringe infusion pumps, by region, 2024
5.9.2.2 Average selling price trend of volumetric infusion pumps, by region, 2022-2024
5.9.2.3 Average selling price trend of insulin pumps, by region, 2022-2024
5.9.2.4 Average selling price trend of ambulatory infusion pumps, by region, 2022-2024
5.9.2.5 Average selling price trend of syringe infusion pumps, by region, 2022-2024
5.9.2.6 Average selling price trend of enteral infusion pumps, by region
5.9.2.7 Average selling price trend of PCA pumps, by region, 2022-2024
5.9.2.8 Average selling price trend of implantable infusion pumps, by region, 2022-2024
5.10 REIMBURSEMENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS, 2025-2026
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 UNMET NEEDS/END-USER EXPECTATIONS
5.14 IMPACT OF AI/GENERATIVE AI ON INFUSION PUMPS MARKET
5.14.1 INTRODUCTION
5.14.2 MARKET POTENTIAL OF INFUSION PUMPS ECOSYSTEM
5.14.3 AI USE CASES
5.14.4 KEY COMPANIES IMPLEMENTING AI IN INFUSION PUMPS
5.14.5 FUTURE OF GEN AI ACROSS INFUSION PUMPS ECOSYSTEM
5.15 ECOSYSTEM MARKET MAP
5.16 CASE STUDY ANALYSIS
5.16.1 RELIABILITY ANALYSIS OF HOSPITAL INFUSION PUMPS
5.16.2 NEXT GENERATION MEDICAL INFUSION PUMP
5.16.3 ENHANCEMENT OF MEDICATION DELIVERY WITH INTEROPERABILITY FEATURES OF SMART INFUSION PUMPS
5.17 SUPPLY/VALUE CHAIN ANALYSIS
5.18 ADJACENT MARKET ANALYSIS
5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.20 INVESTMENT & FUNDING SCENARIO
5.21 TRUMP TARIFF IMPACT ON INFUSION PUMPS MARKET
5.21.1 INTRODUCTION
5.21.2 KEY TARIFF RATES
5.21.3 PRICE IMPACT ANALYSIS
5.21.4 IMPACT ON COUNTRY/REGION
5.21.5 END-USE INDUSTRY IMPACT

6 INFUSION PUMPS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ACCESSORIES AND CONSUMABLES
6.2.1 DEDICATED ACCESSORIES AND CONSUMABLES
6.2.1.1 Volumetric infusion pump dedicated disposables
6.2.1.1.1 Growing installation for deliverance of medication & nutrients to boost demand
6.2.1.2 Insulin pump dedicated disposables
6.2.1.2.1 Rising number of insulin-dependent diabetic patients to support market growth
6.2.1.3 Enteral infusion pump dedicated disposables
6.2.1.3.1 Ability to provide precision & consistency in results to fuel market
6.2.1.4 Syringe infusion pump dedicated disposables
6.2.1.4.1 High demand in emerging economies to drive market
6.2.1.5 Ambulatory infusion pump dedicated disposables
6.2.1.5.1 Growing preference for home care settings to boost demand
6.2.1.6 PCA pump dedicated disposables
6.2.1.6.1 Growing focus on critical pain management to boost market
6.2.1.7 Implantable infusion pump dedicated disposables
6.2.1.7.1 Compatibility features to aid adoption
6.2.2 NON-DEDICATED ACCESSORIES AND CONSUMABLES
6.2.2.1 Infusion catheters
6.2.2.1.1 Potential for recurrent use to drive demand
6.2.2.2 IV administration sets
6.2.2.2.1 Rising demand across various systems to propel market
6.2.2.3 Needleless connectors
6.2.2.3.1 Reduction in bloodstream infection risks to drive demand
6.2.2.4 Cannulas
6.2.2.4.1 Ability to ease patient discomfort to boost demand
6.2.2.5 Tubing and extension sets
6.2.2.5.1 Need for continuous and efficient connections to drive market
6.2.2.6 Valves
6.2.2.6.1 Improvement in infusion quality to drive market
6.2.2.7 Other non-dedicated accessories and consumables
6.3 DEVICES
6.3.1 DEVICES MARKET, BY TYPE
6.3.1.1 Volumetric infusion pumps
6.3.1.1.1 Technological improvements to boost market
6.3.1.2 Insulin pumps
6.3.1.2.1 High demand for diabetes to propel market
6.3.1.3 Ambulatory infusion pumps
6.3.1.3.1 Disposable infusion pumps
6.3.1.3.1.1 Portability & ease of operation to fuel demand
6.3.1.3.2 Chemotherapy infusion pumps
6.3.1.3.2.1 Growing focus on injecting oncology drugs in home care settings to fuel uptake
6.3.1.4 Syringe infusion pumps
6.3.1.4.1 Cost-effectiveness and portability to drive market
6.3.1.5 Enteral infusion pumps
6.3.1.5.1 Technological advancements to bolster market
6.3.1.6 PCA pumps
6.3.1.6.1 Pre-programmed delivery of fixed number of analgesics to fuel adoption
6.3.1.7 Implantable infusion pumps
6.3.1.7.1 Growing use for long-term delivery of opioid medication to drive market
6.3.2 DEVICES MARKET, BY TECHNOLOGY
6.3.2.1 Traditional infusion pumps
6.3.2.1.1 Utilization across long-term care settings to drive market
6.3.2.2 Specialty infusion pumps
6.3.2.2.1 Lightweight mobility to fuel uptake
6.3.3 DEVICES MARKET, BY MODE
6.3.3.1 Stationary infusion pumps
6.3.3.1.1 Ability to deliver medication through multiple routes to support market uptake
6.3.3.2 Portable infusion pumps
6.3.3.2.1 Convenience and remote availability to boost demand

7 INFUSION PUMPS MARKET, BY MODE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 INTRAVENOUS (IV)
7.2.1 RAPID AND CONTROLLED DIRECT DELIVERY TO PROPEL MARKET
7.3 SUBCUTANEOUS
7.3.1 ADMINISTRATION OF MEDICATIONS INTO TISSUE LAYERS FOR SLOW & SUSTAINED RELEASE TO FUEL UPTAKE
7.4 EPIDURAL
7.4.1 ANALGESIC/ANESTHETIC AGENT TRANSMISSION FOR TARGETED PAIN RELIEF TO DRIVE MARKET
7.5 ENTERAL
7.5.1 ADOPTION OF PORTABLE & SMART ENTERAL INFUSION SYSTEMS TO SUPPORT MARKET GROWTH
7.6 INTRATHECAL
7.6.1 MEDICATION DELIVERY FOR CHRONIC PAIN RELIEF & MANAGEMENT TO FUEL UPTAKE

8 INFUSION PUMPS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 HIGH PURCHASING POWER FOR TECHNOLOGICALLY ADVANCED INFUSION DEVICES TO DRIVE MARKET
8.3 HOME CARE SETTINGS
8.3.1 DEVELOPMENT OF COMPACT & PORTABLE DEVICES TO BOOST DEMAND
8.4 AMBULATORY CARE SETTINGS
8.4.1 GROWING AVAILABILITY ACROSS CRITICAL CARE SETTINGS TO DRIVE MARKET
8.5 ACADEMIC & RESEARCH INSTITUTES
8.5.1 INCREASING FOCUS ON R&D ACTIVITIES FOR THERAPEUTIC CLINCIAL TRIALS TO AID MARKET
8.6 ONCOLOGY CENTERS
8.6.1 INCREASING REQUIREMENT FOR PRECISE & CONTROLLED DELIVERY OF CHEOMOTHERAPIC AGENTS TO SUPPORT MARKET GROWTH
8.7 OTHER END USERS

9 INFUSION PUMPS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 CHEMOTHERAPY/ONCOLOGY
9.2.1 HIGH INCIDENCE OF CANCER AND GROWING DEVELOPMENT OF ONCOLOGY THERAPEUTICS TO DRIVE MARKET
9.3 DIABETES MANAGEMENT
9.3.1 INCREASING FOCUS ON SUSTAINED MEDICATION DELIVERY TO BOOST DEMAND
9.4 GASTROENTEROLOGY
9.4.1 INCREASING PREVALENCE OF IBD AND GASTROINTESTINAL INFECTIONS TO FUEL UPTAKE
9.5 ANALGESIA/PAIN MANAGEMENT
9.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO PROPEL MARKET
9.6 PEDIATRICS/NEONATOLOGY
9.6.1 INCREASING INCIDENCE OF PEDIATRIC DIABETES TO SUPPORT MARKET GROWTH
9.7 HEMATOLOGY
9.7.1 INCREASING PREVALENCE OF ANEMIA AND BLOOD DISORDERS TO FUEL UPTAKE
9.8 OTHER APPLICATIONS

10 INFUSION PUMPS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Expansion in home care settings to fuel market
10.2.3 CANADA
10.2.3.1 Increasing incidence of chronic diseases to drive market
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Presence of leading infusion pump manufacturers to drive market
10.3.3 FRANCE
10.3.3.1 Well-established healthcare system to support market growth
10.3.4 UK
10.3.4.1 NHS Digital Strategy and Homecare Shift Accelerate Infusion Pump Adoption in the UK
10.3.5 SPAIN
10.3.5.1 Rising prevalence of cancer to drive demand
10.3.6 ITALY
10.3.6.1 Growing demand for cost-effective home care to drive market
10.3.7 NETHERLANDS
10.3.7.1 Strong healthcare infrastructure and aging population to drive market
10.3.8 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Growing investments in healthcare infrastructure to drive market
10.4.3 JAPAN
10.4.3.1 Large geriatric population to drive demand
10.4.4 INDIA
10.4.4.1 Increasing demand for advanced medical treatment to boost market
10.4.5 THAILAND
10.4.5.1 Medical tourism to drive demand
10.4.6 VIETNAM
10.4.6.1 Rising prevalence of chronic conditions to boost demand
10.4.7 AUSTRALIA
10.4.7.1 Increasing incidence of cancer & diabetes to fuel uptake
10.4.8 SOUTH KOREA
10.4.8.1 Integration of smart technologies to boost demand
10.4.9 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Rising healthcare expenditure to drive market
10.5.3 MEXICO
10.5.3.1 Growth in medical devices industry to fuel market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.2 GCC COUNTRIES
10.6.2.1 Kingdom of Saudi Arabia (KSA)
10.6.2.1.1 Significant healthcare investments to fuel uptake
10.6.2.2 United Arab Emirates (UAE)
10.6.2.2.1 Integration of EMR into smart pumps to fuel adoption
10.6.2.3 Other GCC Countries
10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INFUSION PUMPS MARKET
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.4.1 VOLUMETRIC INFUSION PUMPS MARKET
11.4.2 SYRINGE INFUSION PUMPS MARKET
11.4.3 INSULIN PUMPS MARKET
11.4.4 ENTERAL INFUSION PUMPS MARKET
11.4.5 US: INFUSION PUMPS MARKET SHARE ANALYSIS
11.4.6 EUROPE: INFUSION PUMPS MARKET SHARE ANALYSIS
11.4.7 US: INSULIN PUMPS MARKET SHARE ANALYSIS
11.4.8 RANKING OF KEY MARKET PLAYERS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Product footprint
11.5.5.4 Mode of administration footprint
11.5.5.5 Application footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 DYNAMIC COMPANIES
11.6.3 STARTING BLOCKS
11.6.4 RESPONSIVE COMPANIES
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 Detailed list of key startups/SME players
11.6.5.2 Competitive benchmarking of key emerging players/startups
11.7 BRAND/PRODUCT COMPARATIVE ANALYSIS
11.8 R&D EXPENDITURE OF KEY PLAYERS
11.9 COMPANY VALUATION & FINANCIAL METRICS
11.9.1 FINANCIAL METRICS
11.9.2 COMPANY VALUATION
11.10 COMPETITIVE SCENARIO
11.10.1 PRODUCT LAUNCHES & APPROVALS
11.10.2 DEALS
11.10.3 EXPANSIONS
11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 BECTON, DICKINSON AND COMPANY
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product approvals
12.1.1.3.2 Deals
12.1.1.3.3 Expansions
12.1.1.3.4 Other developments
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 BAXTER INTERNATIONAL, INC.
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches
12.1.2.3.2 Deals
12.1.2.3.3 Other developments
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 B. BRAUN SE
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches & approvals
12.1.3.3.2 Deals
12.1.3.3.3 Other developments
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 MEDTRONIC
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches & approvals
12.1.4.3.2 Deals
12.1.4.4 MnM view
12.1.4.4.1 Key strengths
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 FRESENIUS KABI AG
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Product approvals
12.1.5.3.2 Deals
12.1.5.3.3 Other developments
12.1.5.4 MnM view
12.1.5.4.1 Key strengths
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 ICU MEDICAL, INC.
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches & approvals
12.1.6.3.2 Deals
12.1.6.3.3 Other developments
12.1.7 TERUMO CORPORATION
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches
12.1.7.3.2 Expansions
12.1.7.3.3 Deals
12.1.8 NIPRO
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Expansions
12.1.9 AVANOS MEDICAL, INC.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 INSULET CORPORATION
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Product launches & approvals
12.1.10.3.2 Deals
12.1.10.3.3 Expansions
12.1.11 TANDEM DIABETES CARE, INC.
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.11.3 Recent developments
12.1.11.3.1 Product launches & approvals
12.1.11.3.2 Deals
12.1.12 JMS CO., LTD.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.13 F. HOFFMANN-LA ROCHE LTD.
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.13.3 Recent developments
12.1.13.3.1 Other developments
12.1.14 MOOG, INC.
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.14.2.1 Product launches & enhancements
12.1.14.2.2 Other developments
12.1.15 TELEFLEX INCORPORATED
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.16 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
12.1.16.1 Business overview
12.1.16.2 Products offered
12.1.16.3 Recent developments
12.1.16.3.1 Product launches
12.1.17 YPSOMED
12.1.17.1 Business overview
12.1.17.2 Products offered
12.1.17.3 Recent developments
12.1.17.3.1 Product launches & enhancements
12.1.17.3.2 Deals
12.1.17.3.3 Expansions
12.1.18 POLYMEDICURE
12.1.18.1 Business overview
12.1.18.2 Products offered
12.1.19 ROMSONS.IN
12.1.19.1 Business overview
12.1.19.2 Products offered
12.1.20 PROMED TECHNOLOGY CO., LIMITED
12.1.20.1 Business overview
12.1.20.2 Products offered
12.1.21 MEDCAPTAIN MEDICAL TECHNOLOGY CO., LTD.
12.1.21.1 Business overview
12.1.21.2 Products offered
12.2 OTHER PLAYERS
12.2.1 MICREL MEDICAL DEVICES SA
12.2.2 INTUVIE HOLDINGS LLC
12.2.3 EPIC MEDICAL
12.2.4 SOOIL DEVELOPMENTS CO., LTD.
12.2.5 SHENZHEN MEDRENA BIOTECH CO., LTD
12.2.6 CODAN COMPANIES
12.2.7 EITAN MEDICAL
12.2.8 ANGIPLAST PRIVATE LIMITED
12.2.9 BEIJING KELLYMED CO.

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 RELATED REPORTS
13.4 AUTHOR DETAILS